Blog April 2, 2020
Understanding Legal Trends in the Life Sciences Industry
- Person title
Leading Lawyers on Complying with Regulatory Changes and Keeping Abreast of Supreme Court Decisions
Jon Singer is a renowned life sciences industry leader and acclaimed trial attorney. He heads the firm’s life sciences litigation practice and has been named on of the nation’s finest life sciences trial attorneys.
In this book, “Understanding Legal Trends in the Life Sciences Industry,” his chapter discusses the current challenges and concerns with life sciences intellectual property.
From an intellectual property (IP) perspective, the legal issues in the life sciences industry are many. Probably the most important current question is what can and cannot be patented. A secondary topic of interest is what can and cannot be agreed to in settlement of the major IP cases in life sciences namely, cases under the Hatch Waxman Act between branded and generic pharmaceutical companies. The former touches every patent case in the life sciences from beginning to end; while the latter emerges from the settlement of a patent case and has consequences in antitrust, qui tam, and enforcement litigation.
His chapter is available as a complimentary PDF and can be downloaded here.
The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.
Q&A July 10, 2019
Q&A with Jon Singer for Corporate Counsel Business Journal
Article January 8, 2015
USPTO Guidance on Natural Product Development
Blog December 1, 2023
ITC Monthly Wrap-Up: November 2023
Blog November 27, 2023
Minnesota Patent Litigation Wrap-Up: Q3 2023
Blog November 15, 2023
ITC Monthly Wrap-Up: October 2023
Blog November 9, 2023
Legal Alert: FTC Challenges More Than 100 Patents as Improperly Listed in Orange Book
Blog November 3, 2023
District of Delaware Finds Allergan Patents Invalid for Lack of Written Description and Obviousness-Type Double Patenting in Allergan v. MSN Labs
Blog October 31, 2023
Texas Patent Litigation Monthly Wrap-Up: October 2023
Blog October 30, 2023
District of Delaware Finds Non-Orange Book-Listed Patents Subject to the Same Pleading Standard as Listed Patents in ANDA Infringement Suit
Blog October 11, 2023
ITC Monthly Wrap-Up: September 2023
Blog September 25, 2023
Federal Circuit Evaluates Enablement for Antibody Claims for the First Time Since Amgen v. Sanofi in Baxalta Inc. et al. v. Genentech, Inc.
Blog September 7, 2023
ITC Monthly Wrap-Up: August 2023